Search research articles
Contact Us
Filters
Showing results (71-80 of 100) with videos related to
Page
of 10
Sort By:
European Urology
|
July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
Martin H Voss, Howard Gurney, Vagif Atduev, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2013
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
J Garcia-Donas, L J Leandro-García, A González Del Alba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
José Baselga, Patricia Gómez, Richard Greil, et al.
European Urology
|
June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease
Joaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
Guilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
ESMO Open
|
August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
A Rodriguez-Vida, B P Valderrama, D Castellano, et al.
European Urology
|
August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
Ronald de Wit, David J Vaughn, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 100) with videos related to
Sort By:
Page
of 10
European Urology
|
July 24, 2025
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
Martin H Voss, Howard Gurney, Vagif Atduev, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 22, 2013
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
J Garcia-Donas, L J Leandro-García, A González Del Alba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
José Baselga, Patricia Gómez, Richard Greil, et al.
European Urology
|
June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease
Joaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 9, 2025
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
Guilhem Roubaud, Marie Kostine, Raymond S McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
ESMO Open
|
August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
A Rodriguez-Vida, B P Valderrama, D Castellano, et al.
European Urology
|
August 22, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial
Ronald de Wit, David J Vaughn, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2018
Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
David J Vaughn, Joaquim Bellmunt, Yves Fradet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
J Bellmunt, V Guillem, L Paz-Ares, et al.
Page
of 10